supplementary_material.docx (21.43 kB)
Supplementary Material – Phase II, Clinical Trial of Cabozantinib for the Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplant
dataset
posted on 2022-03-15, 08:51 authored by Figshare Future Science GroupFigshare Future Science Group, Amirhossein Azhie, Robert C. Grant, Michael Herman, Lisa Wang, Jennifer J. Knox, Mamatha Bhat
Allowed Therapies Prohibited or Restricted Therapies Biological specimens (Plans for collection, laboratory evaluation, and storage of specimens) Confidentiality Retention of Patient Records and Study Files |